In this sponsored episode of The Endometriosis Podcast, Dr. Nicholas Fogelson and Dr. Shanti Mohling are joined by Dr. Bruce Lessey—the researcher who identified BCL6 as a marker of endometrial inflammation—and Chris Jackson, CEO of Cicero Diagnostics, the company that brought his discovery to market as the ReceptivaDx test. Together, they explore how a gene first studied in lymphoma research became a tool for detecting progesterone resistance and inflammation linked to endometriosis. The conversation covers how the test works, who it's most useful for, how accurate it is, what its limitations are, and where non-invasive diagnostics for endometriosis may be heading next.

Highlights:

  • What BCL6 is and how it disrupts progesterone signaling and implantation
  • How Dr. Lessey's research became the ReceptivaDX clinical test
  • When this test is most helpful in infertility and recurrent pregnancy loss
  • What a positive result does—and doesn't—mean
  • Why earlier, less invasive diagnosis could change endometriosis care

For clinical consultations: contact Northwest Endometriosis and Pelvic Surgery in Portland, OR at (503) 715-1377 or email us at newpatients@nwendometriosis.com 

Follow us on Instagram: @Nicholasfogelson and @drshantimohling

Download a transcript of this episode.  

 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Nicholas Fogelson and Shanti Mohling. Innehållet i podden är skapat av Nicholas Fogelson and Shanti Mohling och inte av, eller tillsammans med, Poddtoppen.